Author:
Ma Yuxin,Shi Xinhong,Zhao Kun,Hu Shuyi,Shi Yue,Jiang Yingying,Liu Yiling,Lu Lin,Chang Yuting,Zhou Fei,Dai Yingying,Wu Zipeng,Li Shiyi,Qian Zhiying,Xu Xia,Li Chenchen,Shen Bo,Zhou Guoren,Chen Cheng,Wang Xiaohua,Feng Jifeng
Abstract
Metastatic triple-negative breast cancer (mTNBC) has the worst prognosis among breast cancer subtypes. Immune checkpoint inhibitors (ICIs) plus chemotherapy have promising survival benefits. Herein, we report a 51-year-old woman whose metastatic lesions were diagnosed as triple-negative subtype and who received tislelizumab plus eribulin treatment and achieved excellent efficacy. To our knowledge, this study is the first attempt to present tislelizumab in combination with eribulin for mTNBC treatment. New treatments resulting in prolonged survival and durable clinical responses would benefit mTNBC patients. Then, we summarize the possible influencing factors of the interaction between tislelizumab and eribulin.